Respiratory Antiviral Treatment Market

Respiratory Antiviral Treatment Market (Drug Class: Nucleoside Analogs, Neuraminidase Inhibitors, Ion Channel Blockers, and Fusion Protein Inhibitors; Disease Type: Influenza, Bronchiolitis, Pneumonia, Upper Respiratory Tract Infections (URTIs), and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Healthcare Facilities Increase Influenza and COVID-19 Testing Due to Ongoing Flu Season

The coronavirus (COVID-19) outbreak has sparked concern among individuals suffering from influenza. Due to similarities in symptoms, healthcare institutes are increasing awareness about the differences in symptoms. Though influenza and COVID-19 are both contagious respiratory illnesses, they are caused by different viruses. This confusion has created revenue opportunities for companies in the respiratory antiviral treatment market, since infected individuals are seeking professional help from doctors to identify the symptoms.

Influenza is a serious medical issue in western countries. A second wave of COVID-19 in European countries is likely to compromise healthcare facilities. Hence, healthcare professionals are identifying people at high risk of acquiring influenza and COVID-19, and are recommending preventive measures to minimize the pressure in healthcare facilities.

These factors are likely to drive the respiratory antiviral treatment market.

Request a sample to get extensive insights into the Respiratory Antiviral Treatment Market

RSV-associated Clinical Trails Holds Promising Potentials for Development of Bronchiolitis Antivirals

Innovations in the treatment of respiratory syncytial virus (RSV) infection hold promising potentials for the bronchiolitis treatment. For instance, Ark Biosciences— a biotech company specializing in therapeutics for viral infections and respiratory illnesses has announced a successful completion of the phase 2 proof-of-concept study for Ziresovir (AK0529), which is an antiviral agent. Bronchiolitis has led to several hundreds of thousands of deaths worldwide, especially of children under five years of age. Hence, companies in the respiratory antiviral treatment market are increasing their research capabilities to develop therapeutics for bronchiolitis in infants.

Current antiviral agents developed by companies in the respiratory antiviral treatment market are found to have clinical benefits but are not licensed by healthcare institutions. Companies are increasing efforts to develop antivirals that are effective in reducing signs and symptoms of bronchiolitis in infants.

Government-funded Grants Accelerate Development of Influenza Antivirals

Several new direct-acting influenza antivirals have been introduced in the respiratory antiviral treatment market. As such, baloxavir marboxil has been approved in the U.S., which is an antiviral for the treatment of influenza. However, there is a need to develop a universal influenza vaccine. Hence, healthcare companies are increasing their R&D capabilities to propose strategic plans ahead of government agencies with the help of field experts. On the other hand, manufacturers in the respiratory antiviral treatment market are increasing efforts to improve current seasonal influenza vaccines.

In order to tap into incremental opportunities in Europe, manufacturers are developing intravenous zanamivir-like antivirals, which is the only licensed treatment for influenza. This explains why the market is projected to expand at a CAGR of ~6% during the assessment period. Companies are achieving clinical developments in selected neuraminidase inhibitors, host-directed therapies, and selected polymerase inhibitors. Celdara Medical— a biotechnology-based company in the U.S. is gaining recognition for receiving Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop antivirals for COVID-19 and influenza.

Healthcare Providers Adopting Optimal Control Strategies to Overcome Issue of Drug Resistance

The respiratory antiviral treatment market is expected to surpass revenue of US$ 5.3 Bn by the end of 2030. However, the issue of antiviral resistance is emerging as a restraint for market growth. For instance, M2 ion-channel inhibitors and neuraminidase (NA) inhibitors are approved treatments for influenza; however, they are associated with drug resistance in individuals. As such, neuraminidase inhibitors are being used on an extensive scale as an anti-influenza drug, since this treatment is less susceptible to drug resistance.

Since drug resistance has led to increased cost of patient healthcare, companies in the respiratory antiviral treatment market are shifting their business models toward the development of vaccines to curb the spread of respiratory illnesses. Since coinfection of pneumonia and influenza has led to increased morbidity and mortality, healthcare providers are adopting optimal control strategies.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Antiviral Therapies Emerge as Alternative to Influenza Vaccines in High-risk Patients

The antiviral treatment is being highly preferred to shorten the duration of influenza symptoms. Moreover, these antivirals help to decrease the length of hospitals stays and minimizes the risk of complications in patients. As suggested by the CDC (Centers for Disease Control and Prevention), antiviral therapies help to improve medical outcomes in high-risk patients. As such, antiviral chemoprophylaxis is gaining increased popularity for influenza prevention and is being used as an adjunct to vaccination. Companies in the respiratory antiviral treatment market are boosting their output capacity to produce antiviral chemoprophylaxis meant for high-risk patients who cannot receive vaccination due to medical reasons.

Since high-risk patients such as pregnant women are susceptible to contraindications by vaccines, companies in the respiratory antiviral treatment market are increasing awareness about antiviral chemoprophylaxis to treat influenza. Patients with insufficient immune response are also recommended with antiviral chemoprophylaxis.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Respiratory Antiviral Treatment Market

Immunoglobulins with Antiviral Drugs Help Reduce Symptoms of Measles

Companies in the respiratory antiviral treatment market are innovating in antiviral drugs to treat measles. However, their effectiveness after central nervous system (CNS) manifestations remain to be evaluated. Companies in the respiratory antiviral treatment market are experimenting with immunoglobulins to treat measles infection. The combination treatment is being highly publicized for measles treatment, which involves the use of immunoglobulins with antiviral drugs to reduce signs and symptoms.

Ribavirin is a popular antiviral drug used for the treatment of measles infection. The combination of ribavirin and immune serum globulin holds promising potentials to reduce respiratory symptoms of measles. Companies are conducting clinical trials to identify whether the action of vitamin A helps in the treatment of measles. Though vaccines are considered as the most efficient prevention of against measles, the decreasing coverage combined to the increasing number of immunocompromised people difficult to vaccinate confirm the necessity to develop efficient antiviral drugs.

Analysts’ Viewpoint

Healthcare institutes are offering funding to biotech companies to develop antiviral drugs that treat influenza and COVID-19. Direct-acting influenza antivirals are being preferred by healthcare providers to minimize symptoms of respiratory illnesses in patients. However, drug resistance is emerging as a problem in healthcare settings, resulting in increased cost of hospital stay. Hence, companies in the respiratory antiviral treatment market should increase awareness about optimal control strategies such as vaccines and isolation, if patients have low immune response toward antiviral drugs. The combination treatment of immunoglobulins with antiviral drugs helps to reduce signs and symptoms of the measles infection. Ribavirin is being highly publicized as an antiviral drug for the treatment of measles.

Respiratory Antiviral Treatment Market: Overview

  • Antiviral drugs are therapeutics that prevent the development and replication of virus without affecting host cells. These drugs do not destroy their target virus, as it is an obligatory intracellular parasite. Instead, these inhibit their propagation by deactivating viral enzymes.
  • Antiviral drugs are utilized to treat various types of respiratory conditions such as influenza, bronchiolitis, upper respiratory tract infections (URTI), pneumonia, and measles due to their effectiveness
  • The global respiratory antiviral treatment market has experienced significant growth in the last decade due to rise in prevalence of respiratory viral diseases and favorable policies
  • Different types of therapeutics are used in the treatment of respiratory viral diseases, including nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. Neuraminidase inhibitors are most commonly used in the treatment of respiratory viral diseases.

Respiratory Antiviral Treatment: Market Drivers

  • Rise in prevalence and incidence of respiratory viral diseases such as influenza, bronchiolitis, and others drives demand for respiratory antiviral treatment. Incidence and prevalence of flu are gradually increasing across the globe. According to the CDC, around 5% to 20% of the population is affected with the flu in the U.S. every year. Additionally, an estimated 200,000 people are hospitalized due to flu infection in the country every year; of these 36,000 succumb to flu complications.
  • Favorable policies for treatment and prevention of respiratory viral diseases are projected to drive the global respiratory antiviral treatment market during the forecast period. For instance, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) publishes recommendations for high-risk groups. It offers references for use of antiviral agents for treatment and prevention of respiratory viral diseases.

Market Segmentation: Respiratory Antiviral Treatment Market

  • In terms of drug class, the global respiratory antiviral treatment market has been divided into nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. The nucleoside analogs segment has been split into ribavirin, acyclovir, and others. The neuraminidase inhibitors segment has been sub-divided into oseltamivir, zanamivir, and others. The neuraminidase inhibitors segment is anticipated to dominate the global respiratory antiviral treatment market during the forecast period.
  • Based on disease type, the global respiratory antiviral treatment market has been classified influenza, bronchiolitis, pneumonia, upper respiratory tract infections (URTIs), and others (measles, etc.)
  • In terms of distribution channel, the global respiratory antiviral treatment market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global respiratory antiviral treatment market in terms of revenue in 2019.
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and expected revenue (US$ Mn) for each of these segments from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.

Regional Overview: Respiratory Antiviral Treatment Market

  • The global respiratory antiviral treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2018 to 2030, with their CAGRs from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the global respiratory antiviral treatment market, which would help new companies willing to enter the market and existing companies to increase market shares, and in the decision-making process

Major Players

  • The respiratory antiviral treatment market report concludes with the company profiles section, which includes key information about major players in the global respiratory antiviral treatment market
  • Leading players analyzed in the respiratory antiviral treatment market report include
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Takeda Pharmaceutical Company Limited
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Mylan Inc.
    • Merck & Co., Inc.
    • AstraZeneca plc.
  • Each of these players has been profiled in the respiratory antiviral treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Respiratory Antiviral Treatment Market – Segmentation

TMR’s study on the global respiratory antiviral treatment market includes information divided into four segments: drug class, disease type, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global respiratory antiviral treatment market are discussed in detail.

Drug Class

  • Nucleoside Analogs
  • Neuraminidase Inhibitors
  • Ion Channel Blockers
  • Fusion Protein Inhibitors

Disease Type

  • Influenza
  • Bronchiolitis
  • Pneumonia
  • Upper Respiratory Tract Infections (URTIs)
  • Others (Measles, etc.)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of respiratory antiviral treatment market?

Respiratory antiviral treatment market to cross valuation of US$ 5.3 Bn by 2030

What is the anticipated CAGR of the respiratory antiviral treatment market in the forecast period?

Respiratory antiviral treatment market is projected to expand at a CAGR of ~6% from 2020 to 2030

What are the key driving factors for the growth of the respiratory antiviral treatment market?

Respiratory antiviral treatment market is driven by rise in prevalence and incidence of respiratory viral diseases

Which region is expected to project the highest market share in the global respiratory antiviral treatment market?

North America accounted for a major share of the global respiratory antiviral treatment market

Who are the key players in the global respiratory antiviral treatment market?

Key players operating in the global market include F. Hoffmann-La Roche Ltd., Novartis AG, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Teva Pharmaceutical Industries Ltd.

    1. Preface

        1.1. Report Scope and Market Segmentation

        1.2. Research Highlights

    2. Assumptions and Research Methodology

        2.1. Assumptions and Acronyms Used

        2.2. Research Methodology

    3. Executive Summary

    4. Market Overview

        4.1. Introduction

        4.2. Key Industry Developments

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunity

        4.4. Global Respiratory Antiviral Treatment Market Forecast

        4.5. Global Respiratory Antiviral Treatment Market Outlook

    5. Market Outlook

        5.1. Pipeline Analysis

        5.2. Disease Prevalence Rate Globally with Key Countries

        5.3. COVID-19 Impact Analysis

    6. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class

        6.1. Introduction

        6.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

        6.3. Global Respiratory Antiviral Treatment Market Forecast, by Drug Class

            6.3.1. Nucleoside Analogs

                6.3.1.1. Ribavirin

                6.3.1.2. Aciclovir

                6.3.1.3. Others

            6.3.2. Neuraminidase Inhibitors

                6.3.2.1. Oseltamivir

                6.3.2.2. Zanamivir

                6.3.2.3. Others

            6.3.3. Ion Channel Blockers

            6.3.4. Fusion Protein Inhibitors

        6.4. Global Respiratory Antiviral Treatment Market Analysis, by Drug Class

    7. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type

        7.1. Introduction

        7.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

        7.3. Global Respiratory Antiviral Treatment Market Forecast, by Disease Type

            7.3.1. Influenza

            7.3.2. Bronchiolitis

            7.3.3. Pneumonia

            7.3.4. Upper Respiratory Tract Infections (URTIs)

            7.3.5. Others (measles, etc.)

        7.4. Global Respiratory Antiviral Treatment Market Analysis, by Disease Type

    8. Global Respiratory Antiviral Treatment Market Analysis, by Distribution Channel

        8.1. Introduction

        8.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

        8.3. Global Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Pharmacies

        8.4. Global Respiratory Antiviral Treatment Market Analysis, by Route of Administration

    9. Global Respiratory Antiviral Treatment Market Analysis, by Region

        9.1. Global Respiratory Antiviral Treatment Market Scenario, by Region/Country

        9.2. Global Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Region

        9.3. Global Respiratory Antiviral Treatment Market Forecast, by Region

            9.3.1. North America

            9.3.2. Europe

            9.3.3. Asia Pacific

            9.3.4. Latin America

            9.3.5. Middle East & Africa

    10. North America Respiratory Antiviral Treatment Market Analysis

        10.1. North America Respiratory Antiviral Treatment Market Overview

        10.2. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country

        10.3. North America Respiratory Antiviral Treatment Market Forecast, by Country

            10.3.1. U.S.

            10.3.2. Canada

        10.4. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

        10.5. North America Respiratory Antiviral Treatment Market Forecast, by Drug Class

            10.5.1. Nucleoside Analogs

                10.5.1.1. Ribavirin

                10.5.1.2. Aciclovir

                10.5.1.3. Others

            10.5.2. Neuraminidase Inhibitors

                10.5.2.1. Oseltamivir

                10.5.2.2. Zanamivir

                10.5.2.3. Others

            10.5.3. Ion Channel Blockers

            10.5.4. Fusion Protein Inhibitors

        10.6. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

        10.7. North America Respiratory Antiviral Treatment Market Forecast, by Disease Type

            10.7.1. Influenza

            10.7.2. Bronchiolitis

            10.7.3. Pneumonia

            10.7.4. Upper Respiratory Tract Infections (URTIs)

            10.7.5. Others (measles, etc.)

        10.8. North America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

        10.9. North America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

            10.9.1. Hospital Pharmacies

            10.9.2. Retail Pharmacies

            10.9.3. Online Pharmacies

    11. Europe Respiratory Antiviral Treatment Market Analysis

        11.1. Europe Respiratory Antiviral Treatment Market Overview

        11.2. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

        11.3. Europe Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

            11.3.1. Germany

            11.3.2. France

            11.3.3. U.K.

            11.3.4. Italy

            11.3.5. Spain

            11.3.6. Rest of Europe

        11.4. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

        11.5. Europe Respiratory Antiviral Treatment Market Forecast, by Drug Class

            11.5.1. Nucleoside Analogs

                11.5.1.1. Ribavirin

                11.5.1.2. Aciclovir

                11.5.1.3. Others

            11.5.2. Neuraminidase Inhibitors

                11.5.2.1. Oseltamivir

                11.5.2.2. Zanamivir

                11.5.2.3. Others

            11.5.3. Ion Channel Blockers

            11.5.4. Fusion Protein Inhibitors

        11.6. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

        11.7. Europe Respiratory Antiviral Treatment Market Forecast, by Disease Type

            11.7.1. Influenza

            11.7.2. Bronchiolitis

            11.7.3. Pneumonia

            11.7.4. Upper Respiratory Tract Infections (URTIs)

            11.7.5. Others (measles, etc.)

        11.8. Europe Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

        11.9. Europe Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

            11.9.1. Hospital Pharmacies

            11.9.2. Retail Pharmacies

            11.9.3. Online Pharmacies

    12. Asia Pacific Respiratory Antiviral Treatment Market Analysis

        12.1. Asia Pacific Respiratory Antiviral Treatment Market Overview

        12.2. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

        12.3. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

            12.3.1. Japan

            12.3.2. China

            12.3.3. India

            12.3.4. Australia & New Zealand

            12.3.5. Rest of Asia Pacific

        12.4. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

        12.5. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Drug Class

            12.5.1. Nucleoside Analogs

                12.5.1.1. Ribavirin

                12.5.1.2. Aciclovir

                12.5.1.3. Others

            12.5.2. Neuraminidase Inhibitors

                12.5.2.1. Oseltamivir

                12.5.2.2. Zanamivir

                12.5.2.3. Others

            12.5.3. Ion Channel Blockers

            12.5.4. Fusion Protein Inhibitors

        12.6. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

        12.7. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Disease Type

            12.7.1. Influenza

            12.7.2. Bronchiolitis

            12.7.3. Pneumonia

            12.7.4. Upper Respiratory Tract Infections (URTIs)

            12.7.5. Others (measles, etc.)

        12.8. Asia Pacific Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

        12.9. Asia Pacific Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

            12.9.1. Hospital Pharmacies

            12.9.2. Retail Pharmacies

            12.9.3. Online Pharmacies

    13. Latin America Respiratory Antiviral Treatment Market Analysis

        13.1. Latin America Respiratory Antiviral Treatment Market Overview

        13.2. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

        13.3. Latin America Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

            13.3.1. Brazil

            13.3.2. Mexico

            13.3.3. Rest of Latin America

        13.4. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

        13.5. Latin America Respiratory Antiviral Treatment Market Forecast, by Drug Class

            13.5.1. Nucleoside Analogs

                13.5.1.1. Ribavirin

                13.5.1.2. Aciclovir

                13.5.1.3. Others

            13.5.2. Neuraminidase Inhibitors

                13.5.2.1. Oseltamivir

                13.5.2.2. Zanamivir

                13.5.2.3. Others

            13.5.3. Ion Channel Blockers

            13.5.4. Fusion Protein Inhibitors

        13.6. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

        13.7. Latin America Respiratory Antiviral Treatment Market Forecast, by Disease Type

            13.7.1. Influenza

            13.7.2. Bronchiolitis

            13.7.3. Pneumonia

            13.7.4. Upper Respiratory Tract Infections (URTIs)

            13.7.5. Others (measles, etc.)

        13.8. Latin America Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

        13.9. Latin America Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

            13.9.1. Hospital Pharmacies

            13.9.2. Retail Pharmacies

            13.9.3. Online Pharmacies

    14. Middle East & Africa Respiratory Antiviral Treatment Market Analysis

        14.1. Middle East & Africa Respiratory Antiviral Treatment Market Overview

        14.2. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region

        14.3. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Country/Sub-region

            14.3.1. GCC Countries

            14.3.2. South Africa

            14.3.3. Rest of Middle East & Africa

        14.4. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Drug Class

        14.5. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Drug Class

            14.5.1. Nucleoside Analogs

                14.5.1.1. Ribavirin

                14.5.1.2. Aciclovir

                14.5.1.3. Others

            14.5.2. Neuraminidase Inhibitors

                14.5.2.1. Oseltamivir

                14.5.2.2. Zanamivir

                14.5.2.3. Others

            14.5.3. Ion Channel Blockers

            14.5.4. Fusion Protein Inhibitors

        14.6. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Disease Type

        14.7. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Disease Type

            14.7.1. Influenza

            14.7.2. Bronchiolitis

            14.7.3. Pneumonia

            14.7.4. Upper Respiratory Tract Infections (URTIs)

            14.7.5. Others (measles, etc.)

        14.8. Middle East & Africa Respiratory Antiviral Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel

        14.9. Middle East & Africa Respiratory Antiviral Treatment Market Forecast, by Distribution Channel

            14.9.1. Hospital Pharmacies

            14.9.2. Retail Pharmacies

            14.9.3. Online Pharmacies

    15. Competition Landscape

        15.1. Competition Matrix

        15.2. Company Profiles

            15.2.1. F. Hoffmann-La Roche Ltd.

                15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.1.2. Financial Overview

                15.2.1.3. Product Portfolio

                15.2.1.4. SWOT Analysis

                15.2.1.5. Strategic Overview

            15.2.2. Novartis AG

                15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.2.2. Financial Overview

                15.2.2.3. Product Portfolio

                15.2.2.4. SWOT Analysis

                15.2.2.5. Strategic Overview

            15.2.3. Takeda Pharmaceutical Company Limited

                15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.3.2. Financial Overview

                15.2.3.3. Product Portfolio

                15.2.3.4. SWOT Analysis

                15.2.3.5. Strategic Overview

            15.2.4. Pfizer, Inc.

                15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.4.2. Product Portfolio

                15.2.4.3. SWOT Analysis

                15.2.4.4. Strategic Overview

            15.2.5. Teva Pharmaceutical Industries Ltd.

                15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.5.2. Financial Overview

                15.2.5.3. Product Portfolio

                15.2.5.4. SWOT Analysis

                15.2.5.5. Strategic Overview

            15.2.6. Sun Pharmaceutical Industries Ltd.

                15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.6.2. Financial Overview

                15.2.6.3. Product Portfolio

                15.2.6.4. SWOT Analysis

                15.2.6.5. Strategic Overview

            15.2.7. GlaxoSmithKline plc

                15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.7.2. Financial Overview

                15.2.7.3. Product Portfolio

                15.2.7.4. SWOT Analysis

                15.2.7.5. Strategic Overview

            15.2.8. Mylan, Inc.

                15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.8.2. Financial Overview

                15.2.8.3. Product Portfolio

                15.2.8.4. SWOT Analysis

                15.2.8.5. Strategic Overview

            15.2.9. Merck & Co., Inc.

                15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.9.2. Financial Overview

                15.2.9.3. Product Portfolio

                15.2.9.4. SWOT Analysis

                15.2.9.5. Strategic Overview

            15.2.10. AstraZeneca plc.

                15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.10.2. Financial Overview

                15.2.10.3. Product Portfolio

                15.2.10.4. SWOT Analysis

                15.2.10.5. Strategic Overview

    List of Tables

    Table 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 02: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

    Table 03: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

    Table 04: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 05: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 06: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Region, 2018–2030

    Table 07: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country, 2018–2030

    Table 08: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 09: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

    Table 10: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

    Table 11: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 12: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 13: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 14: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 15: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

    Table 16: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

    Table 17: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 18: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 19: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 20: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 21: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

    Table 22: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

    Table 23: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 24: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 25: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 26: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 27: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

    Table 28: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

    Table 29: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 30: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    Table 31: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018–2030

    Table 32: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2018–2030

    Table 33: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Nucleoside Analogs, 2018–2030

    Table 34: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Neuraminidase Inhibitors, 2018–2030

    Table 35: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Disease Type, 2018–2030

    Table 36: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030

    List of Figures

    Figure 01: Global Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast, 2018–2030

    Figure 02: Global Respiratory Antiviral Treatment Market Value Share, by Drug Class, 2019

    Figure 03: Global Respiratory Antiviral Treatment Market Value Share, by Distribution Channel, 2019

    Figure 04: Global Respiratory Antiviral Treatment Market Value Share, by Disease Type, 2019

    Figure 05: Global Respiratory Antiviral Treatment Market Value Share, by Region, 2019

    Figure 06: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 07: Global Respiratory Antiviral Treatment Market Attractiveness, by Drug Class, 2020–2030

    Figure 08: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Nucleoside Analogs, 2018–2030

    Figure 09: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Neuraminidase Inhibitors, 2018–2030

    Figure 10: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Ion Channel Blockers, 2018–2030

    Figure 11: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Fusion Protein Inhibitors, 2018–2030

    Figure 12: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 13: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 14: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Influenza, 2018–2030

    Figure 15: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Bronchiolitis, 2018–2030

    Figure 16: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Pneumonia, 2018–2030

    Figure 17: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Upper Respiratory Tract Infections (URTIs), 2018–2030

    Figure 18: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Others (Measles, etc.), 2018–2030

    Figure 19: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 20: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 21: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030

    Figure 22: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030

    Figure 23: Global Respiratory Antiviral Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2018–2030

    Figure 24: Global Respiratory Antiviral Treatment Market Value Share Analysis, by Region, 2019 and 2030

    Figure 25: Global Respiratory Antiviral Treatment Market Attractiveness Analysis, by Region

    Figure 26: North America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 27: North America Respiratory Antiviral Treatment Market Value Share (%), by Country, 2019 and 2030

    Figure 28: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country, 2020–2030

    Figure 29: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 30: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 31: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 32: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 33: North America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 34: North America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 35: Europe Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 36: Europe Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

    Figure 37: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 38: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 39: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 40: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 41: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 42: Europe Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 43: Europe Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 44: Asia Pacific Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 45: Asia Pacific Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

    Figure 46: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 47: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 48: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 49: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 50: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 51: Asia Pacific Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 52: Asia Pacific Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 53: Latin America Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 54: Latin America Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

    Figure 55: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 56: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 57: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 58: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 59: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 60: Latin America Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 61: Latin America Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

    Figure 62: Middle East & Africa Respiratory Antiviral Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030

    Figure 63: Middle East & Africa Respiratory Antiviral Treatment Market Value Share (%), by Country/Sub-region, 2019 and 2030

    Figure 64: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Country/Sub-region, 2020–2030

    Figure 65: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Drug Class, 2019 and 2030

    Figure 66: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Drug Class, 2020–2030

    Figure 67: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Disease Type, 2019 and 2030

    Figure 68: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Disease Type, 2020–2030

    Figure 69: Middle East & Africa Respiratory Antiviral Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2030

    Figure 70: Middle East & Africa Respiratory Antiviral Treatment Market Attractiveness Analysis, by Distribution Channel, 2020–2030

Copyright © Transparency Market Research, Inc. All Rights reserved